METHOD OF TREATMENT AND COMPOSITIONS COMPRISING A DUAL P13K DELTA-GAMMA KINASE INHIBITOR AND A CORTICOSTEROID

This present disclosure relates to a method of treating autoimmune, respiratory and/or inflammatory diseases or conditions, e.g., asthma, COPD, rheumatoid arthritis and idiopathic pulmonary fibrosis (IPF). The method comprises administering a dual PI3K delta and gamma inhibitor and a corticosteroid. The present invention also relates to pharmaceutical compositions containing a dual PI3K delta and gamma inhibitor and a corticosteroid. 1. A method of treating an autoimmune , respiratory and/or inflammatory disease or condition , the method comprising administering to a subject in need thereof a therapeutically effective amount of (i) a dual PI3K delta and gamma inhibitor , and (ii) a corticosteroid.3. The method according to claim 1 , wherein the corticosteroid is selected from the group consisting of dexamethasone claim 1 , betamethasone claim 1 , prednisolone claim 1 , methyl prednisolone claim 1 , prednisone claim 1 , hydrocortisone claim 1 , fluticasone claim 1 , triamcinolone claim 1 , budesonide or cortisone prednisolone claim 1 , methylprednisolone claim 1 , naflocort claim 1 , deflazacort claim 1 , halopredone acetate claim 1 , budesonide claim 1 , beclomethasone dipropionate claim 1 , hydrocortisone claim 1 , triamcinolone acetonide claim 1 , fluocinolone acetonide claim 1 , fluocinonide claim 1 , clocortolone pivalate claim 1 , methylprednisolone aceponate claim 1 , dexamethasone palmitoate claim 1 , tipredane claim 1 , hydrocortisone aceponate claim 1 , prednicarbate claim 1 , alclometasone dipropionate claim 1 , halometasone claim 1 , methylprednisolone suleptanate claim 1 , mometasone furoate claim 1 , rimexolone claim 1 , prednisolone farnesylate claim 1 , ciclesonide claim 1 , deprodone propionate claim 1 , fluticasone propionate claim 1 , halobetasol propionate claim 1 , loteprednol etabonate claim 1 , betamethasone butyrate propionate claim 1 , flunisolide claim 1 , prednisone claim 1 , dexamethasone sodium phosphate claim 1 , triamcinolone claim 1 , ...

NOVEL 3,5-DISUBSTITUTED-3H-IMIDAZO[4,5-B]PYRIDINE AND 3,5- DISUBSTITUTED -3H-[1,2,3]TRIAZOLO[4,5-B] PYRIDINE COMPOUNDS AS MODULATORS OF C-MET PROTEIN, ETC

The present invention provides compounds useful as c-Met protein kinase modulators, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of c-Met kinase mediated disease or disorders with them. 145-. (canceled)48. A compound of claim 46 , wherein Cyis substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl.51. A compound of claim 46 , wherein Lis —CRR—.52. A compound of claim 51 , wherein Lis —CH— claim 51 , —CH(OH)— claim 51 , —CHF— claim 51 , —CF— claim 51 , —CH(CH)— or —C(CH)—.53. A compound of claim 46 , wherein Lis —CH.56. A compound of claim 47 , wherein Xand Xare CRand Xis independently selected from —CR═CRand —S—.57. A compound of claim 56 , wherein Xis CH claim 56 , Xis CRand Xis —CR═CR claim 56 , wherein Ris hydrogen claim 56 , halogen or substituted or unsubstituted Calkyl.62. A compound of claim 60 , wherein each occurrence of Ris selected from hydrogen claim 60 , halogen and substituted or unsubstituted alkyl.63. A compound of claim 54 , wherein each occurrence of Ris selected from hydrogen claim 54 , fluoro claim 54 , chloro claim 54 , methyl and CFand each occurrence of Ris selected from hydrogen and fluoro.64. A compound of claim 46 , wherein each of Rand Ris hydrogen claim 46 , alkyl or halogen claim 46 , X is N or CRand Ris H claim 46 , substituted or unsubstituted Calkyl claim 46 , NH claim 46 , OH claim 46 , CN or CONH.65. A compound of claim 46 , wherein(a) X is N;{'sup': '2', '(b) Ris H;'}{'sup': a', 'b, 'claim-text': [{'sup': a', 'b, '(ii) Ris methyl and Ris hydrogen,'}, {'sup': a', 'b, '(iii) Ris fluoro and Ris hydrogen,'}, {'sup': a', 'b, '(iv) Rand Rboth are fluoro, or'}, {'sup': a', 'b, '(v) Rand Rboth are methyl; and'}], '(c) (i) both Rand Rare hydrogen,'}{'sup': 'c', '(d) Z is CR, N, S, O, HC═CH— or —N═CH—;'}{'sub': '1', '(e) Zis CH or N;'}{'sub': '2', '(f) Zis C; and'}{'sub': '3', '(g) Zis C or N.'}66. A compound of claim 54 , wherein{'sub': ...

NOVEL 3,5-DISUBSTITUTED-3H-IMIDAZO[4,5-B]PYRIDINE AND 3,5-DISUBSTITUTED-3H-[1,2,3]TRIAZOLO[4,5-B] PYRIDINE COMPOUNDS AS MODULATORS OF C-MET PROTEIN KINASES

The present invention provides compounds useful as c-Met protein kinase modulators, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of c-Met kinase mediated disease or disorders with them. 3. A compound of claim 1 , wherein Cyis substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl.5. (canceled)6. A compound of claim 1 , wherein Lis —CRR—.7. A compound of claim 6 , wherein Lis —CH— claim 6 , —CH(OH)— claim 6 , —CHF— claim 6 , —CF— claim 6 , —CH(CH)— or —C(CH)—.8. (canceled)11. A compound of claim 2 , wherein Xand Xare CRand Xis independently selected from —CR═CRand —S—.12. (canceled)14. (canceled)1719-. (canceled)20. A compound of claim 9 , wherein{'sup': a', 'b, 'each of Rand Ris hydrogen, alkyl or halogen; and'}{'sup': 'c', 'Ris hydrogen or fluoro.'}21. (canceled)22. A compound of claim 9 , wherein{'sup': 'c', 'Z is CR, N, S, O, —HC═CH— or —N═CH—;'}{'sub': '1', 'Zis CH or N;'}{'sub': '2', 'Zis C; and'}{'sub': '3', 'Zis C or N.'}2324-. (canceled)25. A compound of claim 9 , wherein X is N or CRand Ris H claim 9 , substituted or unsubstituted Calkyl claim 9 , NH claim 9 , OH claim 9 , CN or CONH.2630-. (canceled)31. A pharmaceutical composition comprising a compound of and a pharmaceutically acceptable carrier.32. The pharmaceutical composition of claim 31 , further comprising one or more additional therapeutic agents and mixtures thereof.33. The pharmaceutical composition of claim 32 , wherein the one or more additional therapeutic agent is an anti-cancer agent claim 32 , anti-inflammatory agent claim 32 , immunosuppressive agent claim 32 , steroid claim 32 , non-steroidal anti-inflammatory agent claim 32 , antihistamine claim 32 , analgesic claim 32 , or a mixture thereof.3435-. (canceled)36. A method of inhibiting the HGF/c-Met kinase signaling pathway in a cell comprising contacting said cell with a compound of .37. A method of inhibiting the proliferative ...

DUAL SELECTIVE PI3 DELTA AND GAMMA KINASE INHIBITORS

The present invention relates to dual delta (δ) and gamma (γ) PI3K protein kinase modulators, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of Pi3K kinase mediated diseases or disorders with them. 1. A compound selected from 2-(1-(9H-purin-6-ylamino)propyl)-3-(3-fluorophenyl)-4H-chromen-4-one and pharmaceutically acceptable salts thereof.2. A compound selected from (S)-2-(1-(9H-purin-6-ylamino)propyl)-3-(3-fluorophenyl)-4H-chromen-4-one and pharmaceutically acceptable salts thereof.3. The compound according to claim 2 , wherein the compound is substantially free of (R)-2-(1-(9H-purin-6-ylamino)propyl)-3-(3-fluorophenyl)-4H-chromen-4-one claim 2 , and pharmaceutical acceptable salts thereof.4. The compound of claim 2 , wherein the compound has an enantiomeric excess greater than about 95%.5. (S)-2-(1-(9H-purin-6-ylamino)propyl)-3-(3-fluorophenyl)-4H-chromen-4-one.6. The compound of claim 5 , wherein the compound is substantially free of (R)-2-(1-(9H-purin-6-ylamino)propyl)-3-(3-fluorophenyl)-4H-chromen-4-one.7. The compound of claim 5 , wherein the compound has an enantiomeric excess greater than about 95%.8. A pharmaceutical composition comprising a compound of and at least one pharmaceutically acceptable carrier.9. A method of inhibiting a catalytic activity of a PI3 δ kinase present in a cell claim 2 , comprising contacting the cell with an effective amount of a compound of .10. A method of inhibiting a catalytic activity of a PI3 γ kinase present in a cell claim 2 , comprising contacting the cell with an effective amount of a compound of .11. A method of inhibiting a catalytic activity of a PI3 δ kinase and PI3 γ kinase present in a cell claim 2 , comprising contacting the cell with an effective amount of a compound of .12. The method of claim 9 , wherein the inhibition takes place in a subject suffering from a disease claim 9 , disorder or condition selected from cancer claim 9 , a ...

Combination of Anti-CD20 Antibody and PI3 Kinase Selective Inhibitor

Highly effective combinations of a compound of formula A (a PI3Kδ selective inhibitor) and anti-CD20 antibodies are provided herein for the treatment and amelioration of PI3Kδ and/or CD20 mediated diseases and disorders. In particular, the combination can be used to treat cancers and autoimmune diseases. More particularly, the invention provided for a combination of a compound of formula A, or stereoisomers thereof, and ublituximab for the treatment and/or amerioration of hematological malignancies such as leukemia and lymphoma. 159.-. (canceled)61. The method of claim 60 , wherein said antibody or fragment comprises the VH CDR1 claim 60 , CDR2 and CDR3 region of sequences SEQ ID NO:1 claim 60 , 2 claim 60 , and 3 claim 60 , and the VL CDR1 claim 60 , CDR2 and CDR3 region of sequences SEQ ID NO:6 claim 60 , 7 claim 60 , and 8.62. The method of claim 61 , wherein the anti-CD20 antibody or antigen-binding fragment thereof comprises the VH of SEQ ID NO:4 and the VL of SEQ ID NO:9.63. The method of claim 60 , wherein said compound of formula A is (RS)-2-(1-(4-amino-3-(3-fluoro-4-isopropoxyphenyl)-1H-pyrazolo[3 claim 60 ,4-d]pyrimidin-1-yl)ethyl)-6-fluoro-3-(3-fluorophenyl)-4H-chromen-4-one; (S)-2-(1-(4-amino-3-(3-fluoro-4-isopropoxyphenyl)-1H-pyrazolo[3 claim 60 ,4-d]pyrimidin-1-yl)ethyl)-6-fluoro-3-(3-fluorophenyl)-4H-chromen-4-one; or (R)-2-(1-(4-amino-3-(3-fluoro-4-isopropoxyphenyl)-1H-pyrazolo[3 claim 60 ,4-d]pyrimidin-1-yl)ethyl)-6-fluoro-3-(3-fluorophenyl)-4H-chromen-4-one and said anti-CD20 antibody is ublituximab.64. The method of claim 60 , wherein said compound of formula A is (S)-2-(1-(4-amino-3-(3-fluoro-4-isopropoxyphenyl)-1H-pyrazolo[3 claim 60 ,4-d]pyrimidin-1-yl)ethyl)-6-fluoro-3-(3-fluorophenyl)-4H-chromen-4-one and said anti-CD20 antibody is ublituximab.65. A method of inhibiting proliferation of a cell population comprising contacting the population with a combination comprising (i) at least one compound selected from the group consisting of (RS)-2-(1 ...

METHOD OF TREATMENT AND COMPOSITIONS COMPRISING A DUAL PI3K DELTA-GAMMA KINASE INHIBITOR AND A CORTICOSTEROID

This present disclosure relates to a method of treating autoimmune, respiratory and/or inflammatory diseases or conditions, e.g., asthma, COPD, rheumatoid arthritis and idiopathic Pulmonary Fibrosis (IPF). The method comprises administering a dual PI3K delta and gamma inhibitor and a corticosteroid. The present invention also relates to pharmaceutical compositions containing a dual PI3K delta and gamma inhibitor and a corticosteroid. 1. A method of treating an autoimmune , respiratory and/or inflammatory disease or condition , the method comprising administering to a subject in need thereof a therapeutically effective amount of (i) a dual PI3K delta and gamma inhibitor , and (ii) a corticosteroid.3. The method according to claim 1 , wherein the corticosteroid is selected from the group consisting of dexamethasone claim 1 , betamethasone claim 1 , prednisolone claim 1 , methyl prednisolone claim 1 , prednisone claim 1 , hydrocortisone claim 1 , fluticasone claim 1 , triamcinolone claim 1 , budesonide or cortisone prednisolone claim 1 , methylprednisolone claim 1 , naflocort claim 1 , deflazacort claim 1 , halopredone acetate claim 1 , budesonide claim 1 , beclomethasone dipropionate claim 1 , hydrocortisone claim 1 , triamcinolone acetonide claim 1 , fluocinolone acetonide claim 1 , fluocinonide claim 1 , clocortolone pivalate claim 1 , methylprednisolone aceponate claim 1 , dexamethasone palmitoate claim 1 , tipredane claim 1 , hydrocortisone aceponate claim 1 , prednicarbate claim 1 , alclometasone dipropionate claim 1 , halometasone claim 1 , methylprednisolone suleptanate claim 1 , mometasone furoate claim 1 , rimexolone claim 1 , prednisolone farnesylate claim 1 , ciclesonide claim 1 , deprodone propionate claim 1 , fluticasone propionate claim 1 , halobetasol propionate claim 1 , loteprednol etabonate claim 1 , betamethasone butyrate propionate claim 1 , flunisolide claim 1 , prednisone claim 1 , dexamethasone sodium phosphate claim 1 , triamcinolone claim 1 , ...

Combination of Anti-CD20 Antibody and PI3 Kinase Selective Inhibitor

Highly effective combinations of a compound of formula A (a PI3Kδ selective inhibitor) and anti-CD20 antibodies are provided herein for the treatment and amelioration of PI3Kδ and/or CD20 mediated diseases and disorderes. In particular, the combination can be used to treat cancers and autoimmune diseases. More particularly, the invention provided for a combination of a compound of formula A, or stereoisomers thereof, and ublituximab for the treatment and/or amerioration of hematological malignancies such as leukemia and lymphoma. 1. A method of inhibiting proliferation of a CD20-positive cell population comprising contacting the population with a combination comprising(i) a compound selected from the group consisting of 2-(1-(4-amino-3-(3-fluoro-4-isopropoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl)-6-fluoro-3-(3-fluorophenyl)-4H-chromen-4-one and (S)-2-(1-(4-amino-3-(3-fluoro-4-isopropoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl)-6-fluoro-3-(3-fluorophenyl)-4H-chromen-4-one, or a pharmaceutically acceptable salt, solvate, or prodrug of said compound; and(ii) an anti-CD20 antibody or antigen-binding fragment thereof.2. The method of claim 1 , wherein said anti-CD20 antibody or fragment thereof is selected from the group consisting of antibodies and fragments thereof that bind to the same epitope as rituximab claim 1 , ofatumumab claim 1 , ocrelizumab claim 1 , veltuzumab claim 1 , GA101 claim 1 , AME-133v claim 1 , PRO131921 claim 1 , tositumomab claim 1 , hA20 claim 1 , and PRO70769.3. The method of claim 2 , wherein said compound is (S)-2-(1-(4-amino-3-(3-fluoro-4-isopropoxyphenyl)-1H-pyrazolo[3 claim 2 ,4-d]pyrimidin-1-yl)ethyl)-6-fluoro-3-(3-fluorophenyl)-4H-chromen-4-one.4. The method of claim 1 , wherein the population is contacted with(i) a first composition comprising a compound selected from the group consisting of 2-(1-(4-amino-3-(3-fluoro-4-isopropoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl)-6-fluoro-3-(3-fluorophenyl)-4H-chromen-4-one and ...

Combination of Anti-CD20 Antibody and PI3 Kinase Selective Inhibitor

Highly effective combinations of a compound of formula A (a PI3Kδ selective inhibitor) and anti-CD20 antibodies are provided herein for the treatment and amelioration of PI3Kδ and/or CD20 mediated diseases and disorders. In particular, the combination can be used to treat cancers and autoimmune diseases. More particularly, the invention provides for a combination of a compound of formula A, or stereoisomers thereof, and ublituximab for the treatment and/or amerioration of hematological malignancies such as leukemia and lymphoma. The invention also provides for a combination of a compound of formula A, or stereoisomers thereof, and anti-CD20 antibodies, including ublituximab for the treatment and/or amelioration of multiple scelrosis. 1. A method of treating multiple sclerosis which comprises administering to a subject an effective amount of a combination of(i) a compound selected from the group consisting of (RS)-2-(1-(4-amino-3-(3-fluoro-4-isopropoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl)-6-fluoro-3-(3-fluorophenyl)-4H-chromen-4-one and (S)-2-(1-(4-amino-3-(3-fluoro-4-isopropoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl)-6-fluoro-3-(3-fluorophenyl)-4H-chromen-4-one, or a pharmaceutically acceptable salt, solvate, or prodrug of said compound; and(ii) an anti-CD20 antibody or antigen-binding fragment thereof.2. The method of claim 1 , wherein said anti-CD20 antibody or fragment thereof is selected from the group consisting of antibodies and fragments that are or bind the same epitope as ublituximab claim 1 , rituximab claim 1 , ofatumumab claim 1 , ocrelizumab claim 1 , veltuzumab claim 1 , obinutuzumab claim 1 , ocaratuzumab claim 1 , PRO131921 and tositumomab.3. The method of claim 1 , wherein said antibody or fragment thereof comprises the VH CDR1 claim 1 , CDR2 and CDR3 region of sequences SEQ ID NO:1 claim 1 , 2 claim 1 , and 3 claim 1 , and the VL CDR1 claim 1 , CDR2 and CDR3 region of sequences SEQ ID NO:6 claim 1 , 7 claim 1 , and 8.4. The method ...

Novel compounds of 3H-imidazo [4,5-b] pyridine-3,5-disubstituted and 3H- [1,2,3] triazolo [4,5-b] pyridine 3,5-disubstituted as protein kinase modulators

Un compuesto de la fórmula **Fórmula** o un tautómero, estereoisómero, enantiómero, diastereómero, sal o N-óxido del mismo, donde D es arilo monocíclico sustituido o sin sustituir, sustituido por de uno a cinco sustituyentes seleccionados de entre halógeno, alquilo sustituido o sin sustituir o - CONRxRy; cada aparición de Rx y Ry se selecciona independientemente de entre hidrógeno, hidroxi, alquilo sustituido o sin sustituir, alcoxi sustituido o sin sustituir, cicloalquilo sustituido o sin sustituir, anillo heterocíclico sustituido o sin sustituir, arilo sustituido o sin sustituir, arilalquilo sustituido o sin sustituir, heteroarilo sustituido o sin sustituir, y heteroarilalquilo sustituido o sin sustituir, o dos cualesquiera de Rx y Ry que están directamente unidos a un átomo común pueden unirse para formar (i) un grupo oxo (C=O), tio (C=S) o imino (C=NR') (donde R' es H o alquilo) o (ii) un anillo de 3-14 miembros, sustituido o sin sustituir, saturado o insaturado, que puede incluir opcionalmente uno o más heteroátomos que pueden ser iguales o diferentes y se seleccionan de entre O, NR' (donde R' es H o alquilo) o S; cada aparición de R2 es hidrógeno; L2 es -CRaRb-; X es N; Cy2 es **Fórmula** cada aparición de Ra y Rb puede ser igual o diferente y se seleccionan independientemente de entre hidrógeno, halógeno, alquilo C1-6 sustituido o sin sustituir, alquenilo C2-6 sustituido o sin sustituir, alquinilo C2-6 sustituido o sin sustituir, cicloalquilo C3-6 sustituido o sin sustituir, cicloalquilalquilo C3-6 sustituido o sin sustituir, y cicloalquenilo C3-6 sustituido o sin sustituir, o cuando dos sustituyentes Ra y/o Rb están unidos directamente a un átomo común, pueden unirse para formar un anillo de 3-10 miembros sustituto o sin sustituir, saturado o insaturado, que puede incluir opcionalmente uno o más heteroátomos que pueden ser iguales o diferentes y se seleccionan de entre O, NRc o S; y cada aparición de Rc se selecciona independientemente de ...

Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of protein kinases

The present disclosure provides, inter alia, compounds of formula IA and III as protein kinase modulators, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of kinase mediated diseases or disorders with them. Compounds of the disclosure include:3-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzaldehyde, N-(2-Hydroxyethyl)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl) benzamide, Lithium 4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzoate and tert-Butyl 4-(4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamido)piperidine-1-carboxylate

3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of protein kinases

The present invention provides, inter alia, compounds of formula ??,??? and III as protein kinase modulators, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of kinase mediated diseases or disorders with them.

Combination of anti-cd20 antibody and pi3 kinase selective inhibitor

Dual selective PI3 delta and gamma kinase inhibitors

The present invention relates to dual delta (δ) and gamma (γ) PI3K protein kinase modulators, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of Pi3K kinase mediated diseases or disorders with them.

Dual selective pi3 delta and gamma kinase inhibitors

The present invention relates to dual delta (δ) and gamma (γ) PI3K protein kinase modulators, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of Pi3K kinase mediated diseases or disorders with them.

Dual selective PI3 delta and gamma kinase inhibitors

The present invention relates to dual delta (δ) and gamma (γ) PI3K protein kinase modulators, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of Pi3K kinase mediated diseases or disorders with them.

Dual selective pi3 delta and gamma kinase inhibitors

The present invention relates to dual delta (d) and gamma (?) PI3K protein kinase modulators, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of Pi3K kinase mediated diseases or disorders with them.

Combination of anti-cd20 antibody and pi3 kinase selective inhibitor

Highly effective combinations of a compound of formula A (a PI3Kδ selective inhibitor) and anti-CD20 antibodies are provided herein for the treatment and amelioration of PI3Kδ and/or CD20 mediated diseases and disorderes. In particular, the combination can be used to treat cancers and autoimmune diseases. More particularly, the invention provided for a combination of a compound of formula A, or stereoisomers thereof, and ublituximab for the treatment and/or amerioration of hematological malignancies such as leukemia and lymphoma.

Dual selective pi3 delta and gamma kinase inhibitors

The present invention relates to dual delta (.delta.) and gamma (.gamma.) PI3K protein kinase modulators, as reproduced below, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of Pi3K kinase mediated diseases or disorders with them: (see above formula)

compound, compound for use and pharmaceutical composition

a presente invenção refere-se a moduladores de proteína quinase delta (d) e gama (¿) pi3k duplos, métodos de preparação dos mesmos, composições farmacêuticas que contêm os mesmos e métodos de tratamento, prevenção e/ou melhora de doenças ou distúrbios mediados por pi3k quinase com os mesmos. the present invention relates to double delta (d) and gamma (¿) pi3k protein kinase modulators, methods of preparing them, pharmaceutical compositions containing them and methods of treating, preventing and / or ameliorating mediated diseases or disorders by pi3k kinase with them.

Combination of anti-CD20 antibody and PI3 kinase selective inhibitor

Highly effective combinations of a compound of formula A (a PI3Kδ selective inhibitor) and anti-CD20 antibodies are provided herein for the treatment and amelioration of PI3Kδ and/or CD20 mediated diseases and disorderes. In particular, the combination can be used to treat cancers and autoimmune diseases. More particularly, the invention provided for a combination of a compound of formula A, or stereoisomers thereof, and ublituximab for the treatment and/or amerioration of hematological malignancies such as leukemia and lymphoma.

Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of protein kinases

The present disclosure provides, compounds of formula III and IV as protein kinase modulators, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of kinase mediated diseases or disorders with them. Compounds of the disclosure include: N’-(1-(3-(Quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)ethylidene)acetohydrazide

Combination of anti-cd20 antibody and pi3 kinase selective inhibitor

Dual selective pi3 delta and gamma kinase inhibitors

Συνδυασμος αντισωματος αντι-cd20 και εκλεκτικου αναστολεα κινασης p13

Ιδιαιτέρως αποτελεσματικοί συνδυασμοί μιας ένωσης του τύπου Α (εκλεκτικός αναστολέας ΡΙ3Κδ) και αντι-CD20 αντισωμάτων παρέχονται στο παρόν για τη θεραπεία και βελτίωση προκαλούμενων από ΡΙ3Κδ ή/και CD20 ασθενειών και διαταραχών. Ιδιαιτέρως, ο συνδυασμός μπορεί να χρησιμοποιηθεί για να θεραπεύονται καρκίνοι και αυτοάνοσες ασθένειες. Ειδικότερα, η εφεύρεση παρέχεται για συνδυασμό μιας ένωσης του τύπου Α, ή στερεοϊσομερών αυτής, και ουμπλιτουξιμάμπης για τη θεραπεία ή/και βελτίωση αιματολογικών κακοηθειών όπως λευχαιμίας και λεμφώματος.

3,5-disubstituted-3H-imidazo[4,5-B]pyridine and 3,5-disubstituted-3H-[1,2,3]triazolo[4,5-B] pyridine compounds as modulators of c-Met protein kinases

The present invention provides compounds useful as c-Met protein kinase modulators, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of c-Met kinase mediated disease or disorders with them.

Combination of anti-CD20 antibody and PI3 kinase selective inhibitor

Highly effective combinations of a compound of formula A (a PI3Kδ selective inhibitor) and anti-CD20 antibodies are provided herein for the treatment and amelioration of PI3Kδ and/or CD20 mediated diseases and disorders. In particular, the combination can be used to treat cancers and autoimmune diseases. More particularly, the invention provided for a combination of a compound of formula A, or stereoisomers thereof, and ublituximab for the treatment and/or amerioration of hematological malignancies such as leukemia and lymphoma.